Estramustine

DRUG18 trials

Sponsors

SWOG Cancer Research Network, Alliance for Clinical Trials in Oncology, M.D. Anderson Cancer Center, University of Michigan Rogel Cancer Center, Dana-Farber Cancer Institute

Conditions

Adenocarcinoma of the ProstateBreast CancerHormone Resistant Prostate CancerHormone-Refractory Prostate CancerMetastatic Prostate CancerProstate AdenocarcinomaProstate CancerProstatic Neoplasms

Phase 1

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

CompletedNCT00038168

M.D. Anderson Cancer CenterProstate Cancer

Start: 2000-06-30End: 2003-01-31Updated: 2012-08-01

Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma

CompletedNCT00038246

M.D. Anderson Cancer CenterProstate Cancer

Start: 2000-10-31End: 2004-12-31Updated: 2018-10-31

Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer

CompletedNCT00151086

University of Michigan Rogel Cancer CenterProstate Cancer

Start: 2001-12-31End: 2006-08-31Updated: 2015-01-22

Phase 2

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

CompletedNCT00028769

SWOG Cancer Research NetworkProstate Cancer

Start: 2001-12-31End: 2011-07-31Updated: 2013-07-16

Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

CompletedNCT00016913

Alliance for Clinical Trials in OncologyProstate Cancer

Start: 2001-05-31End: 2008-05-31Updated: 2016-07-06

Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate

CompletedNCT00151060

University of Michigan Rogel Cancer CenterProstate Cancer

Start: 1998-12-31End: 2006-06-30Updated: 2015-01-21

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

CompletedNCT00151073

University of Michigan Rogel Cancer CenterHormone-Refractory Prostate Cancer

Start: 2002-04-30End: 2007-09-30Updated: 2015-01-22

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

CompletedNCT00165399

Dana-Farber Cancer InstituteAdenocarcinoma of the Prostate, Prostate Cancer

Start: 2004-03-31End: 2005-12-31Updated: 2018-06-25

Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.

CompletedNCT00183924

University of Southern CaliforniaProstate Adenocarcinoma

Start: 2001-03-31End: 2008-12-31Updated: 2014-05-22

Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

CompletedNCT00193271

SCRI Development Innovations, LLCProstate Cancer

Start: 2004-08-31End: 2007-05-31Target: 30Updated: 2011-05-03

Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

CompletedNCT00193193

SCRI Development Innovations, LLCProstate Cancer

Start: 2000-08-31End: 2007-02-28Target: 100Updated: 2010-08-04

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

CompletedNCT00541281

Cliniques universitaires Saint-Luc- Université Catholique de LouvainHormone Resistant Prostate Cancer, Metastatic Prostate Cancer

Start: 2003-12-31End: 2006-02-28Updated: 2009-10-27

Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer

CompletedNCT01250717

Beth Israel Deaconess Medical CenterProstate Cancer

Start: 2001-01-31End: 2011-05-31Updated: 2014-02-04

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

TerminatedNCT02494713

The University of Texas Health Science Center, HoustonProstate Cancer

Start: 2015-10-31End: 2017-09-14Updated: 2018-11-27

Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer

TerminatedNCT02560051

The University of Texas Health Science Center, HoustonProstatic Neoplasms

Start: 2015-11-30End: 2017-09-14Updated: 2018-11-28

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

WithdrawnNCT02853071

Centre Hospitalier Universitaire de BesanconBreast Cancer

Start: 2017-01-31End: 2020-01-31Updated: 2019-11-18

Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.

CompletedNCT02866955

Institut de Cancérologie de LorraineBreast Cancer

Start: 2011-06-15End: 2015-08-28Updated: 2020-03-09

Phase 3

S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

CompletedNCT00004001

SWOG Cancer Research NetworkProstate Cancer

Start: 1999-10-31End: 2007-01-31Updated: 2014-02-25

Related Papers

Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2019-03-012 citations

The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population

JAMA Oncology2017-06-0630 citations